FIELD NOTE
FDA’s new Olympus warning letter covers six plants in three countries. Two of them are plants the agency already wrote to.
The letter is dated October 7. Olympus disclosed it on October 13, and named the sites: Olympus Medical Systems in Hachioji and Hinode, Aomori Olympus, Shirakawa Olympus, Olympus Winter & IBE in Hamburg, and Gyrus ACMI in Brooklyn Park, Minnesota. Japan, Germany and the US, all from inspections that closed in late 2025. The company says the findings “primarily concern aspects of the company’s quality management system and related processes,” and that the letter challenges the adequacy of its responses to the Form 483 observations those inspections produced.
Read that last part slowly. A warning letter that disputes a company’s 483 responses is not a letter about what inspectors found. It is a letter about whether the agency believes the fix.
What the letter does not do is also on the record. It imposes no restriction on manufacturing, marketing or distribution, requires no recall, and does not block new 510(k) submissions. Olympus will respond within 15 business days, then file periodic updates until FDA judges its actions adequate, and it told investors the letter is not expected to affect financial results. The market took a different view: Tokyo-listed shares fell 13.6 percent on October 14, to 1,756 yen.
The record behind this runs four years and keeps returning to the same addresses. In December 2022 FDA wrote to Olympus Medical Systems about the Hachioji plant, citing four complaints of Uretero-Reno scopes breaking or rupturing during use that the company had not reported inside the 30-day window. In March 2023 it wrote again, about Hinode, citing CAPA failures on a distal cap that was detaching, a 2020 complaint of patient esophageal trauma that went uninvestigated until 2022, 98 complaints never opened under procedure, and six more late reports. Hachioji and Hinode are two of the six sites in the new letter. A third letter, to Aizu Olympus in November 2022, found no written medical device reporting procedures at all, and Aizu is the plant whose output FDA started refusing in June 2025 under Import Alert 89-04, 58 listed device entries covering ureterorenoscopes, bronchoscopes, laparoscopes and automated endoscope reprocessors. In between came a late-2023 Class I recall of more than 17,600 video bronchoscopes after four fires inside patients’ lungs, and a January 2026 recall of three insufflation unit models over software that could over-pressure without alarming, also later classified Class I.
Four years, the same quality system, several of the same plants, and the enforcement ladder has climbed exactly one rung: from letters to a 58-model import alert. That is the part worth sitting with. In that same June 2025 notice, FDA told health care providers they “may continue using these devices if you are not experiencing any problems,” and advised against canceling or delaying procedures without a benefit-risk conversation. In 2025 Olympus held 51.5 percent of the US duodenoscope market and 45.9 percent of gastroscopes. There is no version of a hard stop on Olympus that lands only on Olympus. It lands on GI suites, ICUs and operating rooms. Enforcement against a supplier of that size has a ceiling, and both sides have had four years to work out roughly where it is.
The part worth copying into your own risk register has nothing to do with endoscopes. One inspection campaign produced one letter that reaches a plant in Hamburg and a plant in Minnesota at the same time. FDA is treating a multinational quality system as a single system, which means a finding at a European site is now a US compliance event, and a remediation plan has to satisfy one reviewer across every jurisdiction it touches. Any device company running a shared QMS across borders should assume its exposure is the sum of its sites, not the worst of them.
The timing is the other thing. Olympus is carrying this while cutting roughly 2,000 jobs in a restructuring announced in November 2025, centered on the same endoscopy business the letter covers. Quality remediation is labor. It is documentation, validation, training and the people who do them. Running the largest quality overhaul in the company’s history through a headcount reduction in the same division is a sequencing decision FDA will be grading in writing, every reporting period, until it says otherwise.
SPONSORED BY RŌG HEALTH
A full commercial team for your next milestone.
No hiring required.
A raise, a launch, or a first hospital contract takes more than a good device. It takes messaging that holds up, investor and sales materials, a website, training, and regulatory and manufacturing partners who all understand where the company is headed. Most teams either try to hire for all of it before the milestone or piece it together from vendors who never talk to each other.
RŌG Health gives you that team now. We start with where you’re headed and what’s in the way. Then we bring our own people and a bench of partner firms in regulatory, manufacturing, and commercial execution, all working from the same plan and telling the same story. When the work is done, it adds up to one company instead of six deliverables.
If your next milestone needs more than your current team can carry, book 30 minutes with the RŌG Health team.
Want to put your brand in front of 28,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.